REP-2055

N/A

Report date: 2025/03/19 14:45:50
NME

Base Information

Drug NameREP-2055
Drug Alias NameREP-9ACREP-2055
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBangladeshMoldova, Republic of
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesReplicor Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesReplicor Inc
Active IndicationsN/A
Inactive IndicationsHepatitis B, Chronic

Other Information

ATC CodeN/A
Related LinksN/A